Premium
5‐fluorouracil, doxorubicin, and mitomycin‐C in the treatment of adenocarcinoma and large cell carcinoma of the lung
Author(s) -
Shaw Michael T.,
Shaw Melinda K.
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19870915)60:6<1190::aid-cncr2820600606>3.0.co;2-7
Subject(s) - medicine , adenocarcinoma , mitomycin c , chemotherapy , doxorubicin , fluorouracil , radiation therapy , carcinoma , surgery , adenocarcinoma of the lung , large cell , respiratory disease , small cell carcinoma , lung , disease , oncology , gastroenterology , cancer
Fifty‐four patients with adenocarcinoma and large cell carcinoma of the lung, 16 with localized surgically resected disease and 38 with metastatic disease, were treated with 5‐fluorouracil, doxorubicin, and mitomycin‐C (FAM), in an attempt to prolong previously reported survival times in the patients. The postsurgical patients were given elective chemotherapy. Eighteen received radiation therapy for control of local disease. Tumor regression, attributable to chemotherapy alone, was noted in ten of 20 cases in whom there was measurable disease. The median survival time of all patients was 32 weeks, ranging from 25 weeks in those with distant metastases to 56 weeks in patients with surgically resected disease. FAM did not seem to produce any beneficial survival advantages.